Neuroinflammation represents a hallmark of many degenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, amyotrophic lateral sclerosis, multiple sclerosis, multiple system atrophy and ...

Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and ...

After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S.

ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the ...

Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected ...

Our thoughts are with those who have lost a loved one ...

Research studying the effects of cannabis on the brain has often focused on adolescents, but a new study from CU Anschutz ...

The UAE is rapidly consolidating its position as a global pharmaceutical and life sciences hub, with the national market ...

ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc , a vertically integrated, clinical-stage genetic ...